215 related articles for article (PubMed ID: 19689261)
1. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future.
Weisman LE
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):223-33. PubMed ID: 19689261
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab: where to from here?
Georgescu G; Chemaly RF
Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
[TBL] [Abstract][Full Text] [Related]
3. [Respiratory syncytial virus].
Tsutsumi H
Uirusu; 2005 Jun; 55(1):77-84. PubMed ID: 16308533
[TBL] [Abstract][Full Text] [Related]
4. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
5. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus disease: update on treatment and prevention.
Krilov LR
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
Empey KM; Peebles RS; Kolls JK
Clin Infect Dis; 2010 May; 50(9):1258-67. PubMed ID: 20235830
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
Feltes TF; Sondheimer HM
Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
[TBL] [Abstract][Full Text] [Related]
9. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
Weisman LE
Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
[TBL] [Abstract][Full Text] [Related]
10. Current respiratory syncytial virus prevention strategies in high-risk infants.
Weisman LE
Pediatr Int; 2002 Oct; 44(5):475-80. PubMed ID: 12225544
[TBL] [Abstract][Full Text] [Related]
11. Management of infections caused by respiratory syncytial virus.
Swedish Consensus Group
Scand J Infect Dis; 2001; 33(5):323-8. PubMed ID: 11440215
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
13. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Lagos R; DeVincenzo JP; Muñoz A; Hultquist M; Suzich J; Connor EM; Losonsky GA
Pediatr Infect Dis J; 2009 Sep; 28(9):835-7. PubMed ID: 19636278
[TBL] [Abstract][Full Text] [Related]
14. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
15. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
16. Palivizumab in the prevention of respiratory syncytial virus disease.
Krilov LR
Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus: prospects for new and emerging therapeutics.
Jorquera PA; Tripp RA
Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus infections: recent prospects for control.
Sidwell RW; Barnard DL
Antiviral Res; 2006 Sep; 71(2-3):379-90. PubMed ID: 16806515
[TBL] [Abstract][Full Text] [Related]
19. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.
Hynicka LM; Ensor CR
Ann Pharmacother; 2012 Apr; 46(4):558-66. PubMed ID: 22395247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
